New combo therapy aims to tackle resistant lymphomas
NCT ID NCT07283822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtypes, including peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Participants will receive ruxolitinib for up to one year and pembrolizumab every three weeks, with researchers tracking response rates and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib (a JAK inhibitor) and pembrolizumab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat lymphomas that have not responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial (phase II) with only 53 participants, so results may not apply to everyone. Side effects from the drug combination are possible and are being monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a simple blood test spot lymphoma earlier?
- Can a Five-Drug combo tame a tough lymphoma without standard chemo?
- What happens years after CAR-T therapy? a study aims to find out